Healthcare & Pharmaceutical Market Research in Turkey

BioNixus is a leading healthcare market research company in Turkey, delivering ethics-committee-compliant HCP surveys, KOL mapping, and payer landscape research aligned with TİTCK and SGK requirements. BioNixus combines primary research depth with physician access across major Turkish university hospitals and specialist networks in Istanbul, Ankara, and Izmir.

A healthcare market research company in Turkey designs and executes studies covering physician prescribing behaviour, SGK reimbursement and formulary access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Turkish market.

Turkey operates a largely single-payer social security system administered by SGK (Sosyal Güvenlik Kurumu), which covers the vast majority of the population and sets reimbursement policy nationally rather than regionally. TİTCK (Turkish Medicines and Medical Devices Agency) approval does not guarantee reimbursement — commercial outcomes depend on TİTCK health technology assessment, external reference pricing against a defined basket of comparator countries, and SGK positive list inclusion decisions. The large public Ministry of Health hospital network and a fast-growing private hospital sector both shape prescribing and procurement dynamics, adding strategic complexity distinct from Western European or North American markets.

BioNixus covers oncology, immunology and biologics (including biosimilar uptake under SGK reimbursement policy), cardiovascular, diabetes and metabolic (including GLP-1), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Turkish market.

Yes. BioNixus maintains physician and specialist networks across major Turkish university hospitals and academic medical centres including Hacettepe University Hospital, Istanbul University Hospitals, Ankara University Hospital, and Ege University Hospital. For scarce specialties such as oncology or rare disease, we recruit through university hospital oncology centre networks and specialist directories across both public and private hospital systems.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, ethics committee review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across university hospitals may require extended planning timelines.

Yes. BioNixus designs and executes Turkish patient research in compliance with KVKK (Kişisel Verilerin Korunması Kanunu) data privacy standards and ethics committee (Etik Kurul) research requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with Turkish data protection legislation.

Yes. Turkish modules can run with comparable cells in the USA, UK, EU5 (Germany, France, Italy, Spain), Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner. Turkey's position as a bridge market between Europe and the Middle East makes it a natural anchor point for regional benchmarking programs.